by andrewmm2007 | Dec 8, 2022 | Featured News
Novadip annonce des résultats positifs de l’essai clinique de son traitement expérimental de guérison de fractures osseuses.
by andrewmm2007 | Dec 8, 2022 | Press Releases
MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a...
by andrewmm2007 | Nov 21, 2022 | Featured News
Novadip Biosciences recently received an infusion of €40 million (~USD $40 million) in investments, increasing its total funding to €88 million. The Belgium-based company will use the capital to develop a new class of adipose-derived stem cell (ASC) tissue...
by andrewmm2007 | Nov 7, 2022 | Featured News
Novadip Biosciences raised an additional €40 million (~USD $40 million) in a Series B equity round and non-dilutive funding. This brings the company’s total funding to €88 million, to date.
by andrewmm2007 | Nov 6, 2022 | Featured News
Tissue regeneration biotech Novadip Biosciences raised €40 million. The cash will go toward two clinical-stage programs: an allogeneic bone union therapeutic called NVD-X3 and NVD-003, an autologous bone engraftment product. The cash breaks down to €24 million in...
